This is much higher than the 2.1 rate for bupropion-naltrexone users and 1.1 for sleeve gastrectomy patients [4]
If a diet or drug causes major muscle loss, you might end up thinner but weaker, with a lower resting metabolic rate
Despite extensive animal data suggesting efficacy across depression, anxiety, cognitive decline, and ADHD-relevant models, not a single human clinical trial exists for any mental health application
Potential for Other Conditions Beyond EPP, researchers have explored the use of afamelanotide and other melanocortin agonists for conditions such as vitiligo, a disorder characterised by loss of skin pigmentation, and polymorphous light eruption (PLE), a form of sun allergy
The normalization of GLP-1 microdosing is a slippery slope that once again targets women, promotes thinness even at the cost of our health, and sets us up for failure in the long-term